Common Terminology Criteria for Adverse Events v5.0. v5.0 ed. National Cancer Institute: National Cancer Institute. 2017; Wang Y. Zhou S. Yang F. Qi X. Wang X. Guan X. et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA oncology. 2019; 5: 1008 Bronte E. Bronte G. Novo G. Rinaldi G. Bronte F. Passiglia F. et al. Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. Pharmacology & therapeutics.
